Pharma / Biotech

Does Circadian Rhythm affect the Pharmacokinetics of Once-Daily Tobramycin in Adults with Cystic Fibrosis?



Related Articles

Does Circadian Rhythm affect the Pharmacokinetics of Once-Daily Tobramycin in Adults with Cystic Fibrosis?

Ther Drug Monit. 2020 Feb 11;:

Authors: van Maarseveen EM, van der Meer R, Neef C, Heijerman HGM, Touw DJ

Abstract
BACKGROUND: In the era of multiple daily dosing of systemic aminoglycosides, a circadian rhythm in the clearance of these vital antibiotics has been demonstrated in animals and healthy volunteers. Over the past decade, once-daily dosing regimens have been proved to be less nephrotoxic and were therefore adopted worldwide for most indications requiring treatment with an aminoglycoside. In this study, the effect of time of administration on the pharmacokinetics of once-daily tobramycin in adults with cystic fibrosis (CF) experiencing a pulmonary exacerbation was investigated.
METHODS: In this open randomized study, patients with CF received intravenous tobramycin at 8:00 or 22:00 h. Pharmacokinetic and kidney function parameters were compared between the two groups.
RESULTS: Twenty-five patients were included. The mean weight-corrected clearances of tobramycin were 1.46 vs. 1.43 mL/h*kg (p=0.50) and mean volumes of distribution were 0.25 vs. 0.27 L/kg (p=0.54) for the 8:00 and 22:00 groups, respectively. In addition, no significant differences were detected in changes in estimated clearances of creatinine or tobramycin on day 1 and day 8 in the 8:00 or 22:00 group indicating that there was no decline in clearance over time. At day 8 of therapy, the increase in serum blood urea nitrogen in the 22:00 group was significantly higher than that in the 8:00 group (1.8 vs. 0.2 mmol/L, p=0.015).
CONCLUSIONS: The time of administration (8:00 vs 22:00) did not affect tobramycin pharmacokinetics in the adult CF population studied. The increase in serum blood urea nitrogen in the 22:00 group requires further investigation.

PMID: 32049889 [PubMed – as supplied by publisher]

Source link






Related posts

MORPHINE SULFATE EXTENDED-RELEASE Tablet [Sun Pharmaceutical Industries, Inc.]

Newsemia

Quantitation of Ivosidenib, A Novel Mutant IDH1 Inhibitoron Mice DBS: Application to a Pharmacokinetic Study.

Newsemia

CVS ANTISEPTIC (Cetylpyridinium Chloride) Rinse [CVS Pharmacy, Inc]

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy